Intuitive Surgical, Inc. – Consensus ‘buy’ rating and 20.0% Upside Potential

Broker Ratings
[shareaholic app="share_buttons" id_name="post_below_content"]

Intuitive Surgical, Inc. with ticker code (ISRG) have now 21 analysts in total covering the stock. The consensus rating is pointing to ‘buy’. The range between the high target price and low target price is between 400 and 265 calculating the mean target price we have $332.76. Now with the previous closing price of $277.39 this now indicates there is a potential upside of 20.0%. The 50 day moving average now sits at $291.48 and the 200 moving average now moves to $287.11. The company has a market capitalization of 93.87B. The current share price for the company is: 266.61 USD

The potential market cap would be $112,602,546,242 based on the market consensus.

The company is not paying dividends at this time.

Other points of data to note are a P/E ratio of 66.65, revenue per share of 19.52 and a 7.67% return on assets.

Intuitive Surgical, Inc. develops, manufactures, and markets the da Vinci surgical system and the Ion endoluminal system. The Company’s products and related services enable physicians and healthcare providers to access minimally invasive care. The systems consist of a surgeon console or consoles, a patient-side cart, a vision system, and instruments and accessories. Its da Vinci products consist of five categories, such as da Vinci surgical systems, da Vinci instruments and accessories, da Vinci Stapling, da Vinci Energy, and da Vinci Vision, including Firefly Fluorescence imaging systems and da Vinci Endoscopes. It also provides a suite of systems, learning, and services offerings. Its Ion endoluminal system extends its commercial offerings beyond surgery into diagnostic procedures, enabling minimally invasive biopsies in the lung. Its services include readiness support, maintenance support, perioperative consulting, customer hospital analytics, and market consulting optimization.

Twitter
LinkedIn
Facebook
Email
Reddit
Telegram
WhatsApp
Pocket
Find more news, interviews, share price & company profile here for:

      Search

      Search